# US 2022/0088082 A1 · Compositions and Method for Treating Primary Sclerosing Cholangitis and Related Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088082 A1
- Document ID: US20220088082A1
- Status: Published application
- Kind: A1
- Application number: 17/542,088
- Filed: 2021-12-03
- Published: 2022-03-24
- Earliest claimed: 2016-10-11
- Assignees: Finch Therapeutics Holdings LLC
- Applicants: Finch Therapeutics Holdings LLC
- Inventors: Thomas Julius BORODY
- Web page: https://patentgrep.com/patent/US20220088082A1

## CPC

- A61K 35/24: Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K35/38)
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

## Claims

### Claim 1

A method for treating primary sclerosing cholangitis in a human subject in need thereof, said method comprising orally administering to said human subject a pharmaceutically active dose of a therapeutic composition comprising viable non-pathogenic fecal bacteria or a non-cellular fecal filtrate.

### Claim 2 (depends on 1)

The method of claim 1, wherein said primary sclerosing cholangitis is selected from the group consisting of stage 1, stage 2, stage 3, and stage 4 primary sclerosing cholangitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said therapeutic composition comprises a non-selected fecal microbiota.

### Claim 4 (depends on 3)

The method of claim 3, wherein said fecal microbiota comprises a donor's entire fecal microbiota.

### Claim 5 (depends on 3)

The method of claim 3, wherein said fecal microbiota is from synthetic fecal material.

### Claim 6 (depends on 1)

The method of claim 1, wherein said method reduces the levels of disease indicators selected from the group comprising serum bilirubin, serum aminotransferase, alkaline phosphatase, gamma-glutamyltransferase (GGT), gamma globulin, IgM, serum alkaline phosphatase, or a combination thereof after at least 8 weeks of treatment.

### Claim 7 (depends on 1)

The method of claim 1, wherein said dose is administered at least once daily for at least 2 weeks.

### Claim 8 (depends on 1)

The method of claim 1, wherein said dose is administered at least twice weekly for at least two weeks.

### Claim 9 (depends on 8)

The method of claim 8, wherein said dose is administered at least twice weekly for at least 4 weeks.

### Claim 10 (depends on 8)

The method of claim 8, wherein said dose is administered at least twice weekly for at least 8 weeks.

### Claim 11 (depends on 1)

The method of claim 1, wherein said dose is administered at least three times weekly for at least 4 weeks.

### Claim 12 (depends on 1)

The method of claim 1, wherein said therapeutic composition comprises both live non-pathogenic fecal bacteria and a non-cellular fecal filtrate.

### Claim 13 (depends on 1)

The method of claim 1, wherein said method comprises a first dosing schedule followed by a second dosing schedule, wherein said second dosing schedule comprises a maintenance dose lower or equal to the dose of said first dosing schedule.

### Claim 14 (depends on 1)

The method of claim 1, wherein said therapeutic composition is formulated as a delayed or gradual enteric release form.

### Claim 15 (depends on 1)

The method of claim 1, wherein said therapeutic composition is formulated as an enteric coated capsule or an acid-resistant capsule.

### Claim 16 (depends on 1)

The method of claim 1, wherein said pharmaceutically active dose is from 108 to 1014 cfu or total number of cells.

### Claim 17 (depends on 1)

The method of claim 1, wherein said therapeutic composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, or powder form.

### Claim 18 (depends on 1)

The method of claim 1, wherein said therapeutic composition comprises a cryoprotectant selected from the group consisting of polyethylene glycol, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, alanine, glycine, proline, sucrose, lactose, ribose, trehalose, dimethyl sulfoxide (DMSO), glycerol, and a combination thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein said subject is pretreated with an antibiotic prior to administration of said composition.

### Claim 20 (depends on 1)

The method of claim 1, wherein said method eliminates or reduces one or more symptoms selected from the group consisting of fatigue, itchiness, jaundice, inflammation of the bile ducts, fever, upper abdominal pain, impairment of bile secretion, easy bruising, greasy and foul-smelling stools, gallstones, bile duct stones, anemia, osteoporosis, cirrhosis of the liver, portal hypertension, ascites, liver failure, and cholangiocarcinoma. A method for maintaining treatment efficacy in a subject in need thereof, said method comprising administering to said subject a pharmaceutically active dose of a composition comprising live non-pathogenic fecal bacteria or a non-cellular fecal filtrate.
